AzTrials
AzTrials

Pediatric Heart FailureEarly Phase 1PumpKINNCT02954497

Pumps for Kids, Infants, and Neonates

A Early Phase 1 study testing Surgical placement of the Jarvik 2015 VAD and Surgical Placement of Jarvik 2015 VAD in people with Pediatric Heart Failure, run by Carelon Research at 7 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility trial will enroll 10 subjects at up to 7 sites in the US. Read more about this study

Who is it for?
Any age
Conditions the study is for
Pediatric Heart Failure
What is being tested?
Surgical placement of the Jarvik 2015 VAD and Surgical Placement of Jarvik 2015 VAD
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
7 sitesUnited States
Study dates
22 Oct 2018to 15 Sep 2023
Phase
Early Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Children must meet all of the following criteria:

  1. Males and females within weight range 8 to 30 kg
  2. Body surface area (BSA) 0.4 m2 to 1.0 m2
  3. Cardiac Diagnosis:
  4. Standard Cardiac Anatomy : Two-ventricle circulation, including cardiomyopathy, repaired structural heart disease (e.g. anomalous left coronary artery from the pulmonary artery [ALCAPA], aortic stenosis) or acquired heart disease (e.g., myocarditis, Kawasaki disease)
  5. INTERMACS Profile 1 or 2 as evidenced by one or more of the following:
  6. Inability to wean from extra-corporeal membrane oxygenation (ECMO) or other temporary circulatory support (TCS), OR
  7. Inability to wean from mechanical ventilator support, OR
  8. Inotrope-dependent, decompensated heart failure AND meet one or more of the following criteria within 48 hours prior to implant (unless otherwise noted) which is attributed to decompensated heart failure despite optimal medical therapy:
  9. Urine output <0.5 cc/kg/hour for 12hr within 48 hours ii. Creatinine level >2 times the ULN for age iii. Alanine aminotransferase (ALT) or total bilirubin result >3 times the ULN for age (either qualifies the patient) iv. Mixed venous oxygen saturation (SvO2) <55% (or arteriovenous oxygen difference of >45%) in two repeated measurements v. Acidosis: Base excess >-5 in 2 or more measurements vi. Inability to tolerate appropriate enteral calories as prescribed by a registered dietician d. Inability to ambulate freely to participate fully in age-appropriate activities of daily living (ADLs) and/or cardiac rehabilitation/physical therapy
  10. LVAD support is intended for bridge-to transplant. Subject is listed for transplant or eligible (i.e., no medical or surgical contraindications) to be listed for cardiac transplant, United Network for Organ Sharing (UNOS) status 1A, or equivalent
  11. Written consent of parent(s) or legally authorized representative (LAR) where appropriate.

Children must not meet any of the following exclusion criteria within 48 hours prior to device implant:

  1. Known contraindication for systemic anticoagulation
  2. Currently participating in an interventional trial whose protocol prevents effective application of Jarvik 2015, potentially has an independent effect on trial endpoints, or otherwise interferes with execution of the PumpKIN protocol
  3. Stable inotrope dependence (INTERMACS profile 3)
  4. Single ventricle anatomy
  5. Presence of a mechanical heart valve
  6. Unresolved malignancy
  7. CPR with duration >30 consecutive minutes within 48 hours prior to device implant or CPR with uncertain neurological status prior to device implant
  8. Renal dysfunction that is severe or, in the opinion of the investigator, irreversible
  9. Hepatic dysfunction that is severe or, in the opinion of the investigator, irreversible
  10. Severe or irreversible pulmonary dysfunction
  11. ECMO use for >10 consecutive days
  12. Unrepairable severe aortic insufficiency
  13. Active, systemic infection unresponsive to antimicrobial therapy
  14. Known cerebrovascular event within the past 30 days or uncertain neurological status
  15. Severe right ventricular (RV) dysfunction or significant arrhythmia requiring treatment with an RV assist device (RVAD) (i.e., biventricular assist device)
  16. Unmanageable bleeding per judgment of the investigator
  17. Ventricular dysfunction that is likely to recover (e.g. myocarditis, metabolic myopathy where LV dysfunction is present solely with intermittent acidosis/crises).
  18. Left ventricular end-diastolic dimension or left ventricular end-diastolic volume z score of < +2.5 end-diastolic dimension or ventricular end-diastolic volume z score of < +3.0
  19. Left ventricular ejection fraction of >35%

Trial locations and contacts

7 sites in 1 country.

7 sites in 1 country

United States7 sites
  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30322

  • Boston Children's Hospital

    Boston, Massachusetts, 02115

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229

  • Children's Medical Center - Dallas

    Dallas, Texas, 75235

  • Texas Children's Hospital

    Houston, Texas, 77030

  • Columbia University Medical Center

    New York, New York, 10032

  • Lucile Packard Children's Hospital Stanford

    Palo Alto, California, 94304

Other trials in United States

About this study

PumpKIN is a multicenter, prospective, single-arm feasibility study; Evaluating the investigational Jarvik 2015 VAD in pediatric patients with heart failure. This feasibility trial will enroll 10 subjects at up to 7 sites in the US.

The primary objectives of this investigational device exemption (IDE) clinical investigation are to assess the feasibility of using the Jarvik 2015 in pediatric patients with severe heart failure who require mechanical circulatory support. Feasibility will be assessed by evaluating the safety profile of the Jarvik 2015 device in eligible subjects.

Being tested
Surgical placement of the Jarvik 2015 VAD, Surgical Placement of Jarvik 2015 VAD
Keywords
ventricular assist device, congenital heart disease, heart failure
Medical subject headings
Heart Defects, Congenital, Heart Failure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Surgical placement of the Jarvik 2015 VADDevice

    The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.

  • Surgical Placement of Jarvik 2015 VADProcedure or surgery

    Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.

Study groups in NCT02954497
Study groupRoleWhat they receive
Jarvik 2015 Device VADExperimentalNew, experimental continuous flow VAD
Receives: Device: Surgical placement of the Jarvik 2015 VAD; Procedure: Surgical Placement of Jarvik 2015 VAD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Feasibility

    To assess the clinical feasibility of the investigational Jarvik 2015 VAD by evaluating survival in the absence of severe neurological impairment or death, or device failure up to the clinical endpoint defined as transplant, recovery or 30 days of support

    Measured: 30 days or transplant/recovery (whichever comes first)

  2. Adverse Events

    To evaluate the protocol defined (INTERMACS version 5.0) serious adverse events on Jarvik 2015 support up to transplant, recovery or 30 days of support

    Measured: 30 days or transplant/recovery (whichever comes first)

  3. Technical, surgical, and clinical milestones assessed by feasibility milestones

    To describe the technical, surgical and clinical feasibility by achieving specific technical, surgical, and clinical milestones that typically accompany a successful VAD support run

    Measured: up to 180 days or transplant/recovery

  4. Pivotal Trial continuation assessed by exploratory primary and secondary endpoints

    To evaluate patients with respect to exploratory primary and secondary endpoints to inform the choice of appropriate primary and secondary endpoints for the pivotal trial.

    Measured: 12-months post-explant

Secondary outcomes (26)
  1. Incidence of Adverse Events per patient days of VAD support

    The incidence rate of protocol-defined AEs (INTERMACS, version 5) per patient-day of VAD support up to the first 180 days post-implant.

    Measured: 180 days post-implant

  2. Incidence of Adverse Events related to device

    Incidence rate of protocol-defined AEs possibly, probably, or definitely related to the device per day of mechanical circulatory support, up to the first 180 days post-implant.

    Measured: 180 days post-implant

  3. Neurological dysfunction

    The incidence of new neurological dysfunction up to 180 days post-implant.

    Measured: 180 days post-implant

  4. Pediatric Stroke Outcome Measure Neurological Exam (PSOM-NE) score (0 - 10 scale, higher = worse outcome)

    Pediatric Stroke Outcome Measure-Neurological (PSOM-NE) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.

    Measured: 180 days and 12 months post-explant

  5. King's Outcome Scale for Childhood Head Injury score (0 -5 scale, higher = worse outcome)

    King's Outcome Scale for Childhood Head Injury (KOSCHI) score measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.

    Measured: 180 days and 12 months post-explant

  6. Pediatric Stroke Recurrence and Recovery Questionnaire score (0 -10 scale, higher = worse outcome)

    Pediatric Stroke Recurrence and Recovery Questionnaire (RRQ) measured at 180 days post-implant or immediately prior to explant, and at 12 months post-explant.

    Measured: 180 days and 12 months post-explant

  7. Vineland Adaptive Behavior Scales score (scoring and scale different by domain)

    Vineland Adaptive Behavior Scales (VABS II) measured at 12 months post-explant.

    Measured: 12 months post-explant

  8. Pediatric Quality of Life score (0-4 scale per domain, higher = worse outcome)

    PedsQL20 measured at 180 days post-implant or immediately prior to explant and 12 months post-explant.

    Measured: 12 months post-explant

  9. Ventricular Assist Device Quality of Life score (scoring and scale different per question)

    VAD QL measured at 30 and 90 days post-implant, and every 90 days thereafter, while on Jarvik 2015 VAD support.

    Measured: 30 days, 90 days, 12 months post-explant

  10. Paralytics discontinuation

    Time to discontinuation of paralytics

    Measured: 12 months post-explant

  11. TPN discontinuation

    Time to discontinuation of total parenteral nutrition (TPN)

    Measured: 12 months post-explant

  12. Extubation

    Time to extubation

    Measured: 30 days post-implant

  13. Inotropic agents

    Time to discontinuation of inotropic agents

    Measured: 12 months post-explant

  14. Sedation

    Time to discontinuation of sedation such that subject is alert and interactive (e.g., engaging in age-appropriate play).

    Measured: 30 days post-implant

  15. MRI

    Brain Magnetic Resonance Imaging (MRI) performed 12 months post-explant to assess for clinically silent neurologic injuries.

    Measured: 12 months post-explant

  16. Survival in absence of severe neurological impairment

    Overall survival in the absence of a severe neurologic impairment and in the absence of device failure at 180 days following VAD implant and meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Recovery (removal of VAD and alive at 30 days post-explant), Survival at 180 consecutive days of VAD support

    Measured: 180 days or tranplant/recovery (whichever comes first)

  17. Overall survival in the absence of device failure

    Overall survival in the absence of device failure but without regard for neurologic status, meeting any of the following outcomes: Survival to induction of anesthesia for cardiac transplant surgery, Survival to recovery (removal of Jarvik 2015 VAD and alive at 30 days post-explant), Survival at 180 consecutive days of Jarvik 2015 VAD support

    Measured: 180 days or tranplant/recovery (whichever comes first)

  18. Survival at 30 days post-implant

    Survival at 30 days post-implant

    Measured: 30 days post-implant

  19. Survival at 180 days post-implant

    Survival at 180 days post-implant

    Measured: 180 days post-implant

  20. Survival at 12 months post-explant

    Survival at 12 months post-explant

    Measured: 12 months post-explant

  21. Time to pump failure

    Time to first pump failure

    Measured: device explant

  22. Incidence rate of pump failure

    Incidence rate of pump failures

    Measured: device explant

  23. Time to first pump exchange

    Time to first pump exchanges

    Measured: device explant

  24. Incidence rate of pump exchange

    Incidence rate of pump exchanges

    Measured: device explant

  25. Creatinine level

    Proportion of subjects with a creatinine level below the ULNULN

    Measured: 180 days or immediately prior to explant

  26. ALT level

    Proportion of subjects with an alanine aminotransferase (ALT) level below the ULNULN

    Measured: 180 days or immediately prior to explant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Nov 2016 (estimated)
  2. Study start22 Oct 2018
  3. Primary completion9 Jun 2023
  4. Study completion15 Sep 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Model description
Jarvik 2015
Masking
None (open label)
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02954497
Sponsor's protocol ID
C01367
Acronym
PumpKIN
Status last verified
Nov 2022
First submitted
31 Oct 2016
Last updated
21 Sep 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
Yes: Limited use data set will be made available through NHLBI after the conclusion of the trial.

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing Surgical placement of the Jarvik 2015 VAD and Surgical Placement of Jarvik 2015 VAD in people with Pediatric Heart Failure, run by Carelon Research at 7 sites in United States.

The full registered description is in the About this study section and the official record.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Feasibility (time frame: 30 days or transplant/recovery (whichever comes first)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in